View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 17, 2022

Kriya Therapeutics raises $270m in Series C funding round

The company intends to use the funds to advance its pipeline and scaling of its platforms.

Kriya Therapeutics has raised $270m in a Series C funding round led by Patient Square Capital to progress its fully integrated gene therapy engine.

Bluebird Ventures, Lightswitch Capital, Transhuman Capital, Dexcel Pharma, Foresite Capital, CAM Capital, JDRF T1D Fund, Narya Capital, QVT and other undisclosed investors took part in the financing round.

A gene therapy company, Kriya uses its computational engine, domestic production infrastructure, and integrated design platform for engineering products that could potentially treat a wide range of diseases. 

It has built an ecosystem for offering gene therapy technologies and treatments, with its core business divisions in technology, production, research and development (R&D) and therapeutics. 

The company intends to use the funds to advance its pipeline and progress scaling of its engineering, production and computational platforms.

Kriya Therapeutics co-founder and CEO Shankar Ramaswamy said: “We believe gene therapy has the potential to redefine medicine over the next decade. 

“This financing will support our continued growth as we advance our diverse pipeline into the clinic and further scale our core platforms, to achieve our ultimate vision of expanding the reach and unlocking the full potential of gene therapy as a modality.”

The company had recently launched its scalable GMP manufacturing infrastructure in Research Triangle Park, North Carolina, US, to enable its production from early- to late-stage development. 

This infrastructure also facilitates in developing and deploying new technologies and processes that permit steady, large-scale manufacturing. 

In July last year, Kriya raised $100m in a Series B financing round to advance its platform for designing, developing and producing next-generation gene therapies.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology